Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.

Beyang Therapeutics Co. Ltd. has divulged salts of vascular endothelial growth factor receptor (VEGFR) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory, neurodegeneration, cardiovascular, metabolic and eye disorders.

Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has discovered new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Lunan New Time Biotechnical Co. Ltd. has identified new camptothecin derivatives and their antibody-drug conjugates reported to be useful for the treatment of cancer.

Rezubio Pharmaceuticals Co. Ltd. has reported new drug conjugates comprising lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists covalently linked to a hydrophilic moiety through a linker reported to be useful for the treatment of fibrosis.

Novacell Technology Inc. has identified oligopeptides acting as N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists described as potentially useful for the treatment of cancer and inflammatory disorders.

Gachon University and Jeonbuk National University Industry Foundation have disclosed proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a serine/threonine-protein kinase PAK4-targeting moiety through a linker potentially useful for the treatment of cancer.

Hanmi Holdings Co. Ltd. has patented proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN)-binding moiety coupled to a histone acetyltransferase p300 (EP300)-targeting moiety through a linker acting as EP300 degradation inducers reported to be useful for the treatment of cancer.

Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors have been reported in several Daewoong Pharmaceutical Co. Ltd. patents. They are described as potentially useful for the treatment of cancer and autoimmune diseases.